These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9212918)

  • 1. Pharmacology of therapeutic oligonucleotides.
    Diasio RB; Zhang R
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense therapeutics.
    Agrawal S; Zhao Q
    Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of progress in antisense therapeutics.
    Crooke ST
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.
    Srinivasan SK; Iversen P
    J Clin Lab Anal; 1995; 9(2):129-37. PubMed ID: 7714665
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
    Levin AA
    Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
    [No Abstract]   [Full Text] [Related]  

  • 6. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
    Brysch W; Schlingensiepen KH
    Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic oligonucleotides: the development of antisense therapeutics.
    Monteith DK; Levin AA
    Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo.
    Agrawal S; Zhao Q
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):135-9. PubMed ID: 9593053
    [No Abstract]   [Full Text] [Related]  

  • 9. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
    Iversen PL; Copple BL; Tewary HK
    Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G3139, a BCL-2 antisense oligo-nucleotide, in AML.
    Marcucci G; Stock W; Dai G; Klisovic MI; Maharry K; Shen T; Liu S; Sher DA; Lucas D; Zwiebel A; Larson RA; Caligiuri MA; Bloomfield CD; Chan KK; Grever MR; Byrd JC
    Ann Hematol; 2004; 83 Suppl 1():S93-4. PubMed ID: 15124691
    [No Abstract]   [Full Text] [Related]  

  • 12. Antisense oligonucleotides in cutaneous therapy.
    Wraight CJ; White PJ
    Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
    Henry SP; Monteith D; Bennett F; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):409-20. PubMed ID: 9236856
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to design an antisense oligodeoxynucleotide experiment: a consensus approach.
    Stein CA
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):129-32. PubMed ID: 9593051
    [No Abstract]   [Full Text] [Related]  

  • 16. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Bcl-2 antisense therapy for lymphomas.
    Cotter FE; Waters J; Cunningham D
    Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
    [No Abstract]   [Full Text] [Related]  

  • 18. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antisense strategy--new trends].
    Koziołkiewicz M
    Postepy Biochem; 1998; 44(2):125-35. PubMed ID: 9770236
    [No Abstract]   [Full Text] [Related]  

  • 20. Antisense transforming growth factor-beta 1 in wound healing.
    Chung HT; Choi BM; Jun CD; Park SD; Rim JS
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):257-61. PubMed ID: 9212921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.